Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

First-in-Human Study Testing a New Radioenhancer Using Nanoparticles (NBTXR3) Activated by Radiation Therapy in Patients with Locally Advanced Soft Tissue Sarcomas

Bonvalot, Sylvie, Le Pechoux, Cécile, De Baere, Thierry, Kantor, Guy, Buy, Xavier, Stoeckle, Eberhard, Terrier, Philippe, Sargos, Paul, Coindre, Jean Michel, Lassau, Nathalie, Ait Sarkouh, Rafik, Dimitriu, Mikaela, Borghi, Elsa, Levy, Laurent, Deutsch, Eric, Soria, Jean-Charles · 2017 · Clinical Cancer Research

Published version of a preprint

Abstract

Purpose: This phase I study aimed to determine the recommended dose (RD), safety profile, and feasibility of a procedure combining intratumoral injection of hafnium oxide nanoparticles (NBTXR3; a radioenhancer) and external beam radiotherapy (EBRT) for preoperative treatment of adults with locally advanced soft tissue sarcoma (STS). Experimental Design: Patients had a preoperative indication of EBRT for STS of the extremity or trunk. Baseline tumor volume (TV) was calculated by MRI. NBTXR3 was injected percutaneously into tumors at 53.3 g/L. Dose escalation was based on four levels equivalent to 2.5%, 5%, 10%, and 20% of baseline TV. NBTXR3 was visualized in the tumor 24 hours postinjection, and EBRT was initiated (50 Gy over 5 weeks). Surgery was performed 6 to 8 weeks after EBRT completion. Results: Twenty-two patients completed NBTXR3 injection, EBRT, and surgery and were followed for a median 22 months (range, 6–40). At NBTXR3 20% of TV, two dose-limiting toxicities occurred: injection-site pain and postoperative scar necrosis. The RD was defined as 10%. No leakage of NBTXR3 into surrounding tissues occurred; intratumor NBTXR3 levels were maintained during radiotherapy. At the RD, median tumor shrinkage was 40% (range 71% shrinkage, 22% increase); median percentage of residual viable tumor cells was 26% (range, 10%–90%). Patients receiving 20% of TV demonstrated pathologic complete responses. Seven grade 3 adverse events occurred, which were reversible. Conclusions: A single intratumoral injection of NBTXR3 at 10% of TV with preoperative EBRT was technically feasible with manageable toxicity; clinical activity was observed. Clin Cancer Res; 23(4); 908–17. ©2016 AACR.

Overview

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-16-1297

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 33 references

Cited by

See all 259

Metadata

Authors
Bonvalot, S., Le Pechoux, C., De Baere, T., Kantor, G., Buy, X., Stoeckle, E., Terrier, P., Sargos, P., Coindre, J. M., Lassau, N., Ait Sarkouh, R., Dimitriu, M., Borghi, E., Levy, L., Deutsch, E., & Soria, J.-C.
Affiliations
  • Université Paris Sciences et Lettres (FR)
  • 2Gustave Roussy Cancer Campus, Villejuif, France.
  • Institut Bergonié (FR)
  • Institut Gustave Roussy (FR)
  • 4Nanobiotix, Paris, France.
  • Nanobiotix (France) (FR)
Venue
Clinical Cancer Research
Published
2017-02-14
Volume
23
Issue
4
Pages
908-917
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2529570061
Cited by
243
References
33
Citations by year
2026: 26 · 2025: 24 · 2024: 31 · 2023: 23 · 2022: 36 · 2021: 30 · 2020: 26 · 2019: 23 · 2018: 15 · 2017: 9
FWCI
14.02
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
  • Physical Sciences › Physics and Astronomy › Radiation › Radiation Therapy and Dosimetry
  • Physical Sciences › Physics and Astronomy › Radiation › Advanced Radiotherapy Techniques
Keywords
NBTXR3, hafnium oxide nanoparticles, soft tissue sarcoma, locally advanced sarcoma, preoperative radiotherapy, intratumoral injection, dose escalation, recommended dose, pathological complete response, dose-limiting toxicity, injection site pain
MeSH terms
Adult, Aged, Aged, 80 and over, Combined Modality Therapy, Female, Hafnium, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Oxides, Preoperative Care, Radiotherapy Dosage, Sarcoma, Neoplasm, Residual, Radiotherapy, Adjuvant, Nanoparticles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: First-in-Human Study Testing a New Radioenhancer Using Nanoparticles (NBTXR3) Activated by Radiation Therapy in Patients with Locally Advanced Soft Tissue Sarcomas. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-16-1297
The paper
Bonvalot, S., Le Pechoux, C., De Baere, T., Kantor, G., Buy, X., Stoeckle, E., Terrier, P., Sargos, P., Coindre, J. M., Lassau, N., Ait Sarkouh, R., Dimitriu, M., Borghi, E., Levy, L., Deutsch, E., & Soria, J.-C. (2017). First-in-Human Study Testing a New Radioenhancer Using Nanoparticles (NBTXR3) Activated by Radiation Therapy in Patients with Locally Advanced Soft Tissue Sarcomas. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-16-1297

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.